|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ICU Medical will pay $900 million for the infusion therapy unit rather than $1 billion.
Review of Hospira's ratings remains ongoing. New York, September 03, 2015-- Moody's Investors Service assigned a rating of A1 to the proposed new senior unsecured note offering of Pfizer Inc.. The rating ...
Michael Ball, former chief executive officer Hospira Inc., the biggest injectable-drug maker, made $91.1 million on the sale of his company’s shares to Pfizer Inc. Ball, who had run Lake Forest, Illinois-based ...